ACT-280778
- Generic Name
- ACT-280778
Essential Hypertension
Phase 2
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT01264692
- Locations
- 🇷🇸
Clinical Investigative Site 3001, Belgrade, Serbia
🇷🇸Clinical Investigative Site 3004, Belgrade, Serbia
🇷🇸Clinical Investigative Site 3000, Niska Banja, Serbia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath